Verrica Pharmaceuticals (VRCA) Expected to Release Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.4974) per share and revenue of $6.20 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals Trading Down 1.9%

NASDAQ:VRCA opened at $3.52 on Wednesday. The company has a market cap of $60.47 million, a P/E ratio of -2.11 and a beta of 1.69. Verrica Pharmaceuticals has a twelve month low of $3.08 and a twelve month high of $9.82. The business has a 50 day moving average price of $4.16 and a two-hundred day moving average price of $5.47. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wall Street Zen cut shares of Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Lake Street Capital initiated coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, October 13th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.67.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc. is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals. Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.